Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 11/20 | 0.43 |
| ▸ | DHFR | P00374 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | FABP6 | P51161 | 1/20 | 0.40 |
| ▸ | FPGS | Q05932 | 1/20 | 0.40 |
| ▸ | F7 | P08709 | 2/20 | 0.40 |
| ▸ | F9 | P00740 | 1/20 | 0.40 |
| ▸ | ACP1 | P24666 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | F3 | P13726 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL336448 | 0.91 | TYMS (0.45) | TYMSDHFRABL1FABP6FPGS | |
| SCHEMBL335501 | 0.89 | NPC1 (0.43) | TYMSDHFRABL1FABP6F7 | |
| SCHEMBL336367 | 0.88 | MAPT (0.47) | TYMSDHFRABL1FABP6F7 | |
| SCHEMBL336014 | 0.88 | ABL1 (0.41) | TYMSDHFRABL1FABP6F7 | |
| SCHEMBL335878 | 0.87 | ABL1 (0.43) | TYMSABL1FABP6F7F9 | |
| SCHEMBL335948 | 0.87 | ABL1 (0.45) | ABL1FABP6F7F9ACP1 | |
| SCHEMBL335396 | 0.87 | F7 (0.44) | DHFRF7F9MAPTF3 | |
| SCHEMBL335484 | 0.87 | MAPT (0.43) | TYMSABL1FABP6F7F9 | |
| SCHEMBL335376 | 0.87 | PDE2A (0.45) | TYMSABL1FABP6F7F9 | |
| SCHEMBL335576 | 0.86 | ABL1 (0.43) | TYMSDHFRABL1FABP6F7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069289-B1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS | SANOFI SA (FR) | 2013-10-02 | — | — | EP | claimed |
| US-8097758-B2 | Isoserine derivatives for use as coagulation factor IXa inhibitors | SANOFI-AVENTIS (FR) | 2012-01-17 | — | — | US | claimed |
| US-20090233949-A1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | US | claimed |
| EP-2069289-B1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS | SANOFI SA (FR) | 2013-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233949-A1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS | TFPI, F2, F9 | TYMS 1838/4885DHFR 430/4885ABL1 2660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.